Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.Lancet Oncol. 2015; 16: 1090-1098
- INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.J Clin Oncol. 2002; 20: 1167-1174
- National Comprehensive Cancer Network Guidelines Version 1.2019 Esophageal and Esophagogastric Junction Cancers. National Comprehensive Cancer Network.(Available at:) (Accessed May 22, 2019)
- Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.N Engl J Med. 2001; 345: 725-730
- Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med. 2006; 355: 11-20
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.Lancet. 2019; 393: 1948-1957
- Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.Lancet Oncol. 2018; 19: 616-628
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.Lancet. 2012; 379: 315-321
- Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.J Clin Oncol. 2012; 30: 268-273
- ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).J Clin Oncol. 2019; 37 ([abstract 4001])
- CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.BMC Cancer. 2018; 18: 877
- Four-dimensional computed tomography (4DCT): A review of the current status and applications.J Med Imaging Radiat Oncol. 2015; 59: 545-554
- Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.Int J Radiat Oncol Biol Phys. 2012; 84: 1078-1085
- Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.Int J Radiat Oncol Biol Phys. 2012; 83: 581-586
- Expert consensus contouring guidelines for intensity modulated radiation therapy in esophageal and gastroesophageal junction cancer.Int J Radiat Oncol Biol Phys. 2015; 92: 911-920
- Proton beam therapy and concurrent chemotherapy for esophageal cancer.Int J Radiat Oncol Biol Phys. 2012; 83: e345-e351
- Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience.Adv Radiat Oncol. 2017; 2: 301-307
- Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.Radiother Oncol. 2017; 123: 376-381
- Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation.Int J Part Ther. 2018; 4: 23-32
- Advanced carcinoma of the stomach treated with definitive proton therapy.Am J Gastroenterol. 1990; 85: 443-447
- Definitive proton beam radiation therapy for inoperable gastric cancer: a report of two cases.Radiat Med. 1991; 9: 35-40
- Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators.J Gastrointest Surg. 2000; 4: 567-579
- Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.JAMA. 2007; 297: 267-277
- Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.JAMA. 2010; 304: 1073-1081
- Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.Lancet. 2001; 358: 1576-1585
- Continuing controversy over adjuvant therapy of pancreatic cancer.Lancet. 2001; 358: 1565-1566
- RTOG 0848 Protocol Information.(Available at:) (Accessed May 28, 2019)
- Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101.JAMA Surg. 2016; 151: e161137
- Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.J Clin Oncol. 2008; 26: 3487-3495
- Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.Trials. 2016; 17: 127
- Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1) : A randomized, controlled, multicenter phase III trial.J Clin Oncol. 2018; 36: LBA4002
- National Comprehensive Cancer Network guidelines version 2.2019 pancreatic adenocarcinoma.(Available at:) (Accessed May 28, 2019)
- Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.BMC Cancer. 2017; 17: 505
- Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.JAMA. 2016; 315: 1844-1853
- Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.J Clin Oncol. 2011; 29: 3037-3043
- Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years.Ann Surg. 2001; 234: 63-70
- Prognostic prediction and treatment strategy in hepatocellular carcinoma.Hepatology. 2002; 35: 519-524
- National Comprehensive Cancer Network Guidelines: Hepatobiliary Cancers Version 2.2019.(Available at:) (Accessed May 28, 2019)
- Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial.Int J Radiat Oncol Biol Phys. 2006; 66: 1152-1158
- Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.J Clin Oncol. 2005; 23: 8739-8747
- Radiation treatment outcomes for unresectable hepatocellular carcinoma.Acta Oncol. 2011; 50: 1191-1198
- Intrahepatic cholangiocarcinoma: molecular markers for diagnosis and prognosis.Surg Oncol. 2017; 26: 125-137
- Intrahepatic cholangiocarcinoma: expert consensus statement.HPB (Oxford). 2015; 17: 669-680
- Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis.J Clin Oncol. 2016; 34: 219-226
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.Lancet Oncol. 2016; 17: 1672-1682
- Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.J Clin Oncol. 2009; 27: 3677-3683
- Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype.J Natl Cancer Inst. 2017; 109https://doi.org/10.1093/jnci/djx031
- Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases.Int J Radiat Oncol Biol Phys. 2017; 99: 388-395
- Respiratory gating for liver tumors: use in dose escalation.Int J Radiat Oncol Biol Phys. 2003; 55: 659-668
- Four-dimensional treatment planning and fluoroscopic real-time tumor tracking radiotherapy for moving tumor.Int J Radiat Oncol Biol Phys. 2000; 48: 435-442
- Interfraction liver shape variability and impact on GTV position during liver stereotactic radiotherapy using abdominal compression.Int J Radiat Oncol Biol Phys. 2011; 80: 938-946
- Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy.Int J Radiat Oncol Biol Phys. 2006; 64: 751-759
- Limited role for biliary stent as surrogate fiducial marker in pancreatic cancer: stent and intratumoral fiducials compared.Int J Radiat Oncol Biol Phys. 2014; 89: 641-648
- A multi-institutional experience of MR-guided liver stereotactic body radiation therapy.Adv Radiat Oncol. 2019; 4: 142-149
- Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.Int J Radiat Oncol Biol Phys. 2011; 79: 158-162
- Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC.Adv Radiat Oncol. 2017; 2: 403-415
- Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer.Int J Radiat Oncol Biol Phys. 2012; 83: 901-908
- Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results.Oncotarget. 2017; 8: 59965-59976
- The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience.Ann Surg Oncol. 2015; 22: 2352-2358
- Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience.Cancer. 2009; 115: 5499-5506
- The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial.Cancer. 2011; 117: 3053-3059
- Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol. 2016; 34: 460-468
- Clinical Trials.Gov. National Radiotherapy Group (NRG) GI003.(Available at:) (Accessed May 21, 2019)
- Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head.Int J Radiat Oncol Biol Phys. 2011; 79: 151-157
- A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.Int J Radiat Oncol Biol Phys. 2014; 89: 830-838
- Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.Acta Oncol. 2013; 52: 498-505
- Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.J Gastroenterol. 2014; 49: 1074-1080
- Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.J Clin Oncol. 2012; 30: 1926-1933
- National Comprehensive Cancer Network guidelines version 1.2019 rectal cancer. National Comprehensive Cancer Network.(Available at:) (Accessed April 18, 2019)
- Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.J Clin Oncol. 2012; 30: 3827-3833
- Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.Br J Surg. 2006; 93: 1215-1223
- Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.Lancet Oncol. 2017; 18: 336-346
- Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial.BMC Cancer. 2013; 13: 279
- Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.Lancet Oncol. 2015; 16: 957-966
- Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.J Clin Oncol. 2014; 32: 513-518
- Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.Lancet. 2018; 391: 2537-2545
- Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.JAMA. 2008; 299: 1914-1921
- Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.Ann Oncol. 2014; 25: 1616-1622
- Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.Cancer. 2013; 119: 3769-3775
- RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.Int J Radiat Oncol Biol Phys. 2013; 86: 27-33
- International Standard Randomised Controlled Trials Number (ISRCTN) Registry. PLATO—Personalising anal cancer radiotherapy dose.(Available at:) (Accessed May 21, 2019)
- NRG Oncology Radiation Therapy Oncology Group 0822: a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer.Int J Radiat Oncol Biol Phys. 2015; 93: 29-36
- Proton reirradiation of recurrent rectal cancer: dosimetric comparison, toxicities, and preliminary outcomes.Int J Part Ther. 2014; 1: 2-13
- Outcomes of pencil beam scanning proton therapy for anal cancer: a single institution study.Int J Radiat Oncol Biol Phys. 2019; 103: E9
Available at: https://ascopubs.org/doi/full/10.1200/jco.2012.44.1659.
Available at: https://www.tandfonline.com/doi/full/10.3109/0284186X.2013.820342.
- Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma.PLoS One. 2013; 8: e79854
Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.24059.
Available at: https://linkinghub.elsevier.com/retrieve/pii/S0360-3016(14)03457-9.
Available at: https://www.ncbi.nlm.nih.gov/pubmed/21658854.
Article info
Publication history
Published online: October 30, 2019
Footnotes
Disclosure Statement: Dr J.M. Herman has received research funding from Oncosil, Galera, and Augmenix. He has acted as a scientific advisor for Boston Scientific Corp., Bristol-Myers-Squibb, Astra-Zeneca, Medtronic, and Augmenix. Dr P. Das has received an honorarium from Adlai Nortye. Dr E.B. Holliday receives research support from Merck unrelated to the article. The rest of the authors have no relevant financial or commercial disclosures.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
